UroGen Pharma Reports Q1 2026 Financial Results (8-K)

What Happened

• UroGen Pharma Ltd. (URGN) filed a Form 8‑K on May 6, 2026 (Item 2.02) to announce its results of operations and financial condition for the quarter ended March 31, 2026. A press release summarizing the quarter is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: May 6, 2026; reporting period: quarter ended March 31, 2026 (Q1 2026).
• Press release attached as Exhibit 99.1; interactive XBRL cover page included as Exhibit 104.
• The 8‑K is limited to results disclosure and exhibits (Item 2.02 and Item 9.01) — no other material events (e.g., executive changes or transactions) are reported in this filing.

Why It Matters

• Quarterly earnings and related disclosures can affect UroGen’s stock price and investor decisions because they provide updated information on revenue, expenses, cash position and operational progress.
• Retail investors should review the attached press release (Exhibit 99.1) and monitor subsequent filings (e.g., the company’s 10‑Q) for full financial statements, details on revenue, net income/loss, cash runway, and any guidance.